{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:44:40Z","timestamp":1760028280928,"version":"3.37.3"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10557-020-07015-8","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T10:03:14Z","timestamp":1591696994000},"page":"707-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Angiotensin Receptor Neprilysin Inhibitors\u20142019 Update"],"prefix":"10.1007","volume":"34","author":[{"given":"George","family":"Chalikias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-9181","authenticated-orcid":false,"given":"Dimitrios","family":"Tziakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"7015_CR1","unstructured":"Entresto. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/entresto-epar-summary-public_en.pdf. Accessed 20 Mar 2020."},{"key":"7015_CR2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-019-01181-2","volume":"79","author":"E Fabris","year":"2019","unstructured":"Fabris E, Merlo M, Rapezzi C, et al. Sacubitril\/valsartan: updates and clinical evidence for a disease-modifying approach. Drugs. 2019;79:1543\u201356.","journal-title":"Drugs."},{"key":"7015_CR3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/phar.2075","volume":"38","author":"KR Smith","year":"2018","unstructured":"Smith KR, Hsu CC, Berei TJ, et al. PARADIGM-HF Trial: secondary analyses address unanswered questions. Pharmacotherapy. 2018;38:284\u201398.","journal-title":"Pharmacotherapy."},{"key":"7015_CR4","doi-asserted-by":"crossref","unstructured":"Carballo D, Stirnemann J, Garin N, Marti C, Serratrice J, Carballo S. Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure. ESC Heart Fail. 2020;7(3):1282\u20131290.","DOI":"10.1002\/ehf2.12676"},{"key":"7015_CR5","doi-asserted-by":"crossref","unstructured":"Nordberg-Backelin C, Fu M, Ljungman C. Early experience of sacubitril-valsartan in heart failure with reduced ejection fraction in real-world clinical setting. ESC Heart Fail. 2020;7(3):1049\u20131055.","DOI":"10.1002\/ehf2.12644"},{"key":"7015_CR6","first-page":"25","volume":"7","author":"F de Frutos","year":"2020","unstructured":"de Frutos F, Mirabet S, Ortega-Paz L, et al. Management of heart failure with reduced ejection fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry. ESC Heart Fail. 2020;7:25\u201335.","journal-title":"ESC Heart Fail"},{"key":"7015_CR7","doi-asserted-by":"publisher","unstructured":"Nandal S, Chow CL, Hannah V, Vaddadi G, Van Gaal W. Tolerability and efficacy of sacubitril\/valsartan in clinical practice. Intern Med J. 2020. https:\/\/doi.org\/10.1111\/imj.14749.","DOI":"10.1111\/imj.14749"},{"key":"7015_CR8","first-page":"158","volume":"7","author":"RB Pharithi","year":"2020","unstructured":"Pharithi RB, Ferre-Vallverdu M, Maisel AS, et al. Sacubitril-Valsartan in a routine community population: attention to volume status critical to achieving target dose. ESC Heart Fail. 2020;7:158\u201366.","journal-title":"ESC Heart Fail"},{"key":"7015_CR9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.regg.2019.10.002","volume":"55","author":"A Esteban-Fern\u00e1ndez","year":"2020","unstructured":"Esteban-Fern\u00e1ndez A, D\u00edez-Villanueva P, Vicent L, et al. Sacubitril\/valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Rev Esp Geriatr Gerontol. 2020;55:65\u20139.","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"7015_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchf.2019.08.003","volume":"8","author":"NY Tan","year":"2020","unstructured":"Tan NY, Sangaralingham LR, Sangaralingham SJ, Yao X, Shah ND, Dunlay SM. Comparative effectiveness of sacubitril-valsartan versus ACE\/ARB therapy in heart failure with reduced ejection fraction. JACC Heart Fail. 2020;8:43\u201354.","journal-title":"JACC Heart Fail"},{"key":"7015_CR11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2459\/JCM.0000000000000889","volume":"21","author":"X Chen","year":"2020","unstructured":"Chen X, Schaufelberger M, Fu M. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016. J Cardiovasc Med (Hagerstown). 2020;21:6\u201312.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"7015_CR12","doi-asserted-by":"crossref","first-page":"6745074","DOI":"10.1155\/2019\/6745074","volume":"2019","author":"H Norberg","year":"2019","unstructured":"Norberg H, Bergdahl E, Lindmark K. Safety and tolerability of initiating maximum-dose sacubitril-valsartan in patients on target dose renin-angiotensin system inhibitors. Cardiovasc Ther. 2019;2019:6745074.","journal-title":"Cardiovasc Ther"},{"key":"7015_CR13","first-page":"407","volume":"31","author":"\u00d2 Mir\u00f3","year":"2019","unstructured":"Mir\u00f3 \u00d2, Mart\u00edn-S\u00e1nchez FJ, Jacob J, Herrero-Puente P, Gil V, Llorens P. Grupo de Investigaci\u00f3n ICA-SEMES Sacubitril\/valsartan-treated patients with exacerbated acute heart failure: approaches to care in the emergency department and on the ward. Emergencias. 2019;31:407\u201312.","journal-title":"Emergencias"},{"issue":"11","key":"7015_CR14","doi-asserted-by":"crossref","first-page":"e005691","DOI":"10.1161\/CIRCHEARTFAILURE.118.005691","volume":"12","author":"AF Mohanty","year":"2019","unstructured":"Mohanty AF, Levitan EB, Dodson JA, et al. Characteristics and healthcare utilization among veterans treated for heart failure with reduced ejection fraction who switched to sacubitril\/valsartan. Circ Heart Fail. 2019;12(11):e005691.","journal-title":"Circ Heart Fail"},{"key":"7015_CR15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/ehf2.12527","volume":"6","author":"JC L\u00f3pez-Azor","year":"2019","unstructured":"L\u00f3pez-Azor JC, Vicent L, Valero-Masa MJ, et al. Safety of sacubitril\/valsartan initiated during hospitalization: data from a non-selected cohort. ESC Heart Fail. 2019;6:1161\u20136.","journal-title":"ESC Heart Fail"},{"key":"7015_CR16","first-page":"1","volume":"7","author":"P Martens","year":"2019","unstructured":"Martens P, Verluyten L, Van de Broek H, et al. Determinants of maximal dose titration of sacubitril\/valsartan in clinical practice. Acta Cardiol. 2019;7:1\u201310.","journal-title":"Acta Cardiol"},{"key":"7015_CR17","doi-asserted-by":"publisher","unstructured":"Akerman CC, Beavers JC. Risk factors for intolerance of inpatient sacubitril\/valsartan initiation. J Pharm Pract. 2019;897190019878948. https:\/\/doi.org\/10.1177\/0897190019878948.","DOI":"10.1177\/0897190019878948"},{"key":"7015_CR18","doi-asserted-by":"crossref","unstructured":"Jorsal A, Pryds K, McMurray JJV, et al. Optimizing heart failure treatment following cardiac resynchronization therapy. Clin Res Cardiol. 2020;109(5):638\u2013645.","DOI":"10.1007\/s00392-019-01553-4"},{"key":"7015_CR19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1074248419872958","volume":"25","author":"FC Hsiao","year":"2020","unstructured":"Hsiao FC, Wang CL, Chang PC, Lu YY, Huang CY, Chu PH. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: real-world experience from Taiwan. J Cardiovasc Pharmacol Ther. 2020;25:152\u20137.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"7015_CR20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/phar.2328","volume":"39","author":"J Han","year":"2019","unstructured":"Han J, Chung F, Nguyen QL, Mody FV, Jackevicius CA. Evaluation of patients with heart failure to determine eligibility for treatment with sacubitril\/valsartan: insights from a Veterans Administration Healthcare System. Pharmacotherapy. 2019;39:1053\u20139.","journal-title":"Pharmacotherapy."},{"key":"7015_CR21","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ejhf.1532","volume":"21","author":"CJ Kapelios","year":"2019","unstructured":"Kapelios CJ, Lainscak M, Savarese G, et al. Heart Failure Long-Term Registry Investigators. Sacubitril\/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency\/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. Eur J Heart Fail. 2019;21:1383\u201397.","journal-title":"Eur J Heart Fail"},{"key":"7015_CR22","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ehf2.12452","volume":"6","author":"B Atallah","year":"2019","unstructured":"Atallah B, Sadik ZG, Hisham M, et al. A per-protocol initiation of sacubitril\/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region. ESC Heart Fail. 2019;6:758\u201363.","journal-title":"ESC Heart Fail"},{"key":"7015_CR23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.1465","volume":"21","author":"R Wachter","year":"2019","unstructured":"Wachter R, Fonseca AF, Balas B, et al. Real-world treatment patterns of sacubitril\/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail. 2019;21:588\u201397.","journal-title":"Eur J Heart Fail"},{"key":"7015_CR24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cardfail.2019.03.011","volume":"25","author":"S Adie","year":"2019","unstructured":"Adie S, Bitar A, Hanigan S, Pogue K, Koelling T, Dorsch M. Real-world prevalence of adverse events after initiating sacubitril\/valsartan compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in systolic heart failure. J Card Fail. 2019;25:412\u20133.","journal-title":"J Card Fail"},{"key":"7015_CR25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10557-019-06873-1","volume":"33","author":"J Simpson","year":"2019","unstructured":"Simpson J, Benson L, Jhund PS, Dahlstr\u00f6m U, McMurray JJV, Lund LH. \u201cReal world\u201d eligibility for sacubitril\/valsartan in unselected heart failure patients: data from the Swedish Heart Failure Registry. Cardiovasc Drugs Ther. 2019;33:315\u201322.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"sup1","key":"7015_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/03007995.2019.1576485","volume":"35","author":"C Parisi","year":"2019","unstructured":"Parisi C, De Giusti M, Castello L, Dito E, Proietti F, Tomai F. Sacubitril\/valsartan: preliminary experience in post-acute stabilized patients with reduced ejection fraction heart failure. Curr Med Res Opin. 2019;35(sup1):17\u201320.","journal-title":"Curr Med Res Opin"},{"key":"7015_CR27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/FJC.0000000000000665","volume":"73","author":"G Pinto","year":"2019","unstructured":"Pinto G, Tondi L, Gemma M, et al. Real-life indications to sacubitril\/valsartan treatment in patients with chronic systolic heart failure. J Cardiovasc Pharmacol. 2019;73:301\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7015_CR28","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s11845-019-01990-0","volume":"188","author":"A Daly","year":"2019","unstructured":"Daly A, Coughlan JJ, Mross T, Wafer M, O\u2019Connor A, Liston R. Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities. Ir J Med Sci. 2019;188:1169\u201374.","journal-title":"Ir J Med Sci"},{"issue":"3","key":"7015_CR29","doi-asserted-by":"crossref","first-page":"e010484","DOI":"10.1161\/JAHA.118.010484","volume":"8","author":"N Luo","year":"2019","unstructured":"Luo N, Lippmann SJ, Mentz RJ, et al. Relationship between hospital characteristics and early adoption of angiotensin-receptor\/neprilysin inhibitor among eligible patients hospitalized for heart failure. J Am Heart Assoc. 2019;8(3):e010484.","journal-title":"J Am Heart Assoc"},{"key":"7015_CR30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FJC.0000000000000641","volume":"73","author":"L Vicent","year":"2019","unstructured":"Vicent L, Esteban-Fern\u00e1ndez A, G\u00f3mez-Bueno M, De-Juan J, et al. Sacubitril\/valsartan in daily clinical practice: data from a prospective registry. J Cardiovasc Pharmacol. 2019;73:118\u201324.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7015_CR31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/FJC.0000000000000643","volume":"73","author":"AX Du","year":"2019","unstructured":"Du AX, Westerhout CM, McAlister FA, et al. Titration and tolerability of sacubitril\/valsartan for patients with heart failure in clinical practice. J Cardiovasc Pharmacol. 2019;73:149\u201354.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7015_CR32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/00015385.2018.1473825","volume":"74","author":"P Martens","year":"2019","unstructured":"Martens P, Lambeets S, Lau CW, Dupont M, Mullens W. Impact of sacubitril\/valsartan on heart failure admissions: insights from real-world patient prescriptions. Acta Cardiol. 2019;74:115\u201322.","journal-title":"Acta Cardiol"},{"key":"7015_CR33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00059-018-4690-6","volume":"44","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Ariano C, Di Biase G, Noutsias M. In: HFREF patients, sacubitril\/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization: a retrospective cohort study. Herz. 2019;44:651\u20138.","journal-title":"Herz."},{"key":"7015_CR34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00059-017-4671-1","volume":"44","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Ariano C, Di Biase G, Noutsias M. Sacubitril\/valsartan for heart failure with reduced left ventricular ejection fraction: a retrospective cohort study. Herz. 2019;44:425\u201332.","journal-title":"Herz."},{"key":"7015_CR35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","volume":"21","author":"O Vardeny","year":"2019","unstructured":"Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019;21:337\u201341.","journal-title":"Eur J Heart Fail"},{"key":"7015_CR36","doi-asserted-by":"crossref","unstructured":"Cacciatore F, Amarelli C, Maiello C, et al. Sacubitril\/valsartan in patients listed for heart transplantation: effect on physical frailty. ESC Heart Fail. 2020;7(2):757\u2013762.","DOI":"10.1002\/ehf2.12610"},{"key":"7015_CR37","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.3390\/jcm8122165","volume":"8","author":"G Romano","year":"2019","unstructured":"Romano G, Vitale G, Ajello L, et al. The effects of sacubitril\/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure with reduced ejection fraction: the \u201chemodynamic recovery\u201d. J Clin Med. 2019;8:2165.","journal-title":"J Clin Med"},{"issue":"sup3","key":"7015_CR38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/03007995.2019.1598702","volume":"35","author":"NR Pugliese","year":"2019","unstructured":"Pugliese NR, Fabiani I, Zywicki V, et al. Effects of sacubitril\/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction \u226435. Curr Med Res Opin. 2019;35(sup3):13\u20138.","journal-title":"Curr Med Res Opin"},{"key":"7015_CR39","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320.","journal-title":"N Engl J Med"},{"key":"7015_CR40","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","volume":"21","author":"R Wachter","year":"2019","unstructured":"Wachter R, Senni M, Belohlavek J, et al. TRANSITION Investigators. Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21:998\u20131007.","journal-title":"Eur J Heart Fail"},{"key":"7015_CR41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al. PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539\u201348.","journal-title":"N Engl J Med"},{"key":"7015_CR42","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamacardio.2019.4665","volume":"5","author":"AD DeVore","year":"2019","unstructured":"DeVore AD, Braunwald E, Morrow DA, et al. PIONEER-HF Investigators. Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: secondary analysis of the open-label extension of the PIONEER-HF Trial. JAMA Cardiol. 2019;5:202\u20137.","journal-title":"JAMA Cardiol"},{"key":"7015_CR43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ejhf.1670","volume":"22","author":"M Senni","year":"2020","unstructured":"Senni M, Wachter R, Witte KK, et al. TRANSITION Investigators. Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. Eur J Heart Fail. 2020;22:303\u201312.","journal-title":"Eur J Heart Fail"},{"key":"7015_CR44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, Vaduganathan M, Claggett BL, et al. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141:352\u201361.","journal-title":"Circulation."},{"key":"7015_CR45","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","volume":"141","author":"JJV McMurray","year":"2020","unstructured":"McMurray JJV, Jackson AM, Lam CSP, et al. Effects of Sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation. 2020;141:338\u201351.","journal-title":"Circulation."},{"key":"7015_CR46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","volume":"75","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Desai AS, et al. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF. J Am Coll Cardiol. 2020;75:245\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"7015_CR47","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1161\/CIRCULATIONAHA.119.039920","volume":"140","author":"S Selvaraj","year":"2019","unstructured":"Selvaraj S, Claggett B, Pozzi A, et al. Prognostic implications of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF. Circulation. 2019;140:1369\u201379.","journal-title":"Circulation."},{"key":"7015_CR48","first-page":"1","volume":"322","author":"AS Desai","year":"2019","unstructured":"Desai AS, Solomon SD, Shah AM, et al. EVALUATE-HF Investigators. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322:1\u201310.","journal-title":"JAMA."},{"key":"7015_CR49","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2019.02.015","volume":"7","author":"C Balmforth","year":"2019","unstructured":"Balmforth C, Simpson J, Shen L, et al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC Heart Fail. 2019;7:457\u201365.","journal-title":"JACC Heart Fail"},{"key":"7015_CR50","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","volume":"139","author":"DA Morrow","year":"2019","unstructured":"Morrow DA, Velazquez EJ, DeVore AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF Trial. Circulation. 2019;139:2285\u20138.","journal-title":"Circulation."},{"key":"7015_CR51","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamacardio.2019.4982","volume":"5","author":"A Sumarsono","year":"2019","unstructured":"Sumarsono A, Vaduganathan M, Ajufo E, et al. Contemporary patterns of Medicare and Medicaid utilization and associated spending on sacubitril\/valsartan and ivabradine in heart failure. JAMA Cardiol. 2019;5:336\u20139.","journal-title":"JAMA Cardiol"},{"key":"7015_CR52","doi-asserted-by":"publisher","unstructured":"Perera K, Ademi Z, Liew D, Zomer E. Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis. Eur J Prev Cardiol. 2019;2047487319878953. https:\/\/doi.org\/10.1177\/2047487319878953.","DOI":"10.1177\/2047487319878953"},{"key":"7015_CR53","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jval.2019.06.007","volume":"22","author":"S van der Pol","year":"2019","unstructured":"van der Pol S, de Jong LA, Vemer P, Jansen DEMC, Postma MJ. Cost-effectiveness of sacubitril\/valsartan in Germany: an application of the efficiency frontier. Value Health. 2019;22:1119\u201327.","journal-title":"Value Health"},{"key":"7015_CR54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14737167.2019.1628642","volume":"20","author":"M Borges","year":"2020","unstructured":"Borges M, Afonso-Silva M, Laires PA, et al. Cost-effectiveness of sacubitril\/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal. Expert Rev Pharmacoecon Outcomes Res. 2020;20:199\u2013205.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"7015_CR55","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.clinthera.2019.04.031","volume":"41","author":"SK Park","year":"2019","unstructured":"Park SK, Hong SH, Kim H, Kim S, Lee EK. Cost-utility analysis of sacubitril\/valsartan use compared with standard care in chronic heart failure patients with reduced ejection fraction in South Korea. Clin Ther. 2019;41:1066\u201379.","journal-title":"Clin Ther"},{"key":"7015_CR56","doi-asserted-by":"crossref","first-page":"e011089","DOI":"10.1161\/JAHA.118.011089","volume":"8","author":"NM Albert","year":"2019","unstructured":"Albert NM, Swindle JP, Buysman EK, Chang C. Lower hospitalization and healthcare costs with sacubitril\/valsartan versus angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker in a retrospective analysis of patients with heart failure. J Am Heart Assoc. 2019;8:e011089.","journal-title":"J Am Heart Assoc"},{"key":"7015_CR57","first-page":"102","volume":"22","author":"M Correale","year":"2019","unstructured":"Correale M, Monaco I, Ferraretti A, et al. Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry. Int J Cardiol Heart Vasc. 2019;22:102\u20134.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"7015_CR58","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","volume":"75","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj S, Claggett BL, B\u00f6hm M, et al. Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan. J Am Coll Cardiol. 2020;75:1644\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"7015_CR59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/jch.13437","volume":"21","author":"Y Huo","year":"2019","unstructured":"Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril\/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2019;21:67\u201376.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"7015_CR60","doi-asserted-by":"crossref","first-page":"e16093","DOI":"10.1097\/MD.0000000000016093","volume":"98","author":"Q Li","year":"2019","unstructured":"Li Q, Li L, Wang F, et al. Effect and safety of LCZ696 in the treatment of hypertension: a meta-analysis of 9 RCT studies. Medicine (Baltimore). 2019;98:e16093.","journal-title":"Medicine (Baltimore)"},{"key":"7015_CR61","first-page":"214","volume":"67","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Ariano C, Soreca S. Antihypertensive effect of sacubitril\/valsartan: a meta-analysis. Minerva Cardioangiol. 2019;67:214\u201322.","journal-title":"Minerva Cardioangiol"},{"key":"7015_CR62","doi-asserted-by":"crossref","first-page":"24","DOI":"10.14740\/cr813","volume":"10","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Soreca S, Ariano C. Anti-hypertensive effect of sacubitril\/valsartan: a meta-analysis of randomized controlled trials. Cardiol Res. 2019;10:24\u201333.","journal-title":"Cardiol Res"},{"key":"7015_CR63","first-page":"100486","volume":"27","author":"M Correale","year":"2020","unstructured":"Correale M, Mallardi A, Mazzeo P, et al. Sacubitril\/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: the Daunia Heart Failure Registry. Int J Cardiol Heart Vasc. 2020;27:100486.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"7015_CR64","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10557-019-06858-0","volume":"33","author":"C Moliner-Ab\u00f3s","year":"2019","unstructured":"Moliner-Ab\u00f3s C, Rivas-Lasarte M, Pamies Besora J, et al. Sacubitril\/valsartan in real-life practice: experience in patients with advanced heart failure and systematic review. Cardiovasc Drugs Ther. 2019;33:307\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7015_CR65","doi-asserted-by":"crossref","unstructured":"Lee S, Oh J, Kim H, et al. Sacubitril\/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail. 2020;7(3):1125\u20131129.","DOI":"10.1002\/ehf2.12659"},{"key":"7015_CR66","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.nefro.2019.01.005","volume":"39","author":"B Quiroga","year":"2019","unstructured":"Quiroga B, de Santos A, Sapiencia D, Saharaui Y, \u00c1lvarez-Chiva V. Sacubitril\/valsartan in chronic kidney disease, the nephrologist point of view. Nefrologia. 2019;39:646\u201352.","journal-title":"Nefrologia."},{"key":"7015_CR67","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","volume":"74","author":"HY Chang","year":"2019","unstructured":"Chang HY, Feng AN, Fong MC, et al. Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74:372\u201380.","journal-title":"J Cardiol"},{"key":"7015_CR68","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Garcia A, L\u00f3pez-Fern\u00e1ndez T, Mitroi C, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail. 2020;7(2):763\u2013767.","DOI":"10.1002\/ehf2.12627"},{"key":"7015_CR69","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.recesp.2019.07.015","volume":"73","author":"A Mart\u00edn-Garc\u00eda","year":"2020","unstructured":"Mart\u00edn-Garc\u00eda A, D\u00edaz-Pel\u00e1ez E, Mart\u00edn-Garc\u00eda AC, S\u00e1nchez-Gonz\u00e1lez J, Ib\u00e1\u00f1ez B, S\u00e1nchez PL. Myocardial function and structure improvement with sacubitril\/valsartan in cancer therapy-induced cardiomyopathy. Rev Esp Cardiol (Engl Ed). 2020;73:268\u20139.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"7015_CR70","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1177\/1078155218783238","volume":"25","author":"CE Sheppard","year":"2019","unstructured":"Sheppard CE, Anwar M. The use of sacubitril\/valsartan in anthracycline-induced cardiomyopathy: a mini case series. J Oncol Pharm Pract. 2019;25:1231\u20134.","journal-title":"J Oncol Pharm Pract"},{"key":"7015_CR71","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2019.06.031","volume":"300","author":"SJ Maurer","year":"2020","unstructured":"Maurer SJ, Pujol Salvador C, Schiele S, Hager A, Ewert P, Tutarel O. Sacubitril\/valsartan for heart failure in adults with complex congenital heart disease. Int J Cardiol. 2020;300:137\u201340.","journal-title":"Int J Cardiol"},{"key":"7015_CR72","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/2150135119825599","volume":"10","author":"G Lluri","year":"2019","unstructured":"Lluri G, Lin J, Reardon L, Miner P, Whalen K, Aboulhosn J. Early experience with sacubitril\/valsartan in adult patients with congenital heart disease. World J Pediatr Congenit Heart Surg. 2019;10:292\u20135.","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"7015_CR73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.hlc.2018.12.003","volume":"29","author":"V Appadurai","year":"2020","unstructured":"Appadurai V, Thoreau J, Malpas T, Nicolae M. Sacubitril\/valsartan in adult congenital heart disease patients with chronic heart failure\u2014a single centre case series and call for an international registry. Heart Lung Circ. 2020;29:137\u201341.","journal-title":"Heart Lung Circ"},{"key":"7015_CR74","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","volume":"139","author":"DH Kang","year":"2019","unstructured":"Kang DH, Park SJ, Shin SH, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation. 2019;139:1354\u201365.","journal-title":"Circulation."},{"key":"7015_CR75","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3390\/jcm8101582","volume":"8","author":"I El-Battrawy","year":"2019","unstructured":"El-Battrawy I, Pilsinger C, Liebe V, et al. Impact of sacubitril\/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients. J Clin Med. 2019;8:1582.","journal-title":"J Clin Med"},{"key":"7015_CR76","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00380-019-01454-6","volume":"35","author":"L Vicent","year":"2020","unstructured":"Vicent L, M\u00e9ndez-Zurita F, Vi\u00f1olas X, et al. Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril\/valsartan initiation. Heart Vessel. 2020;35:136\u201342.","journal-title":"Heart Vessel"},{"key":"7015_CR77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000497190","volume":"142","author":"L Vicent","year":"2019","unstructured":"Vicent L, Ju\u00e1rez M, Bru\u00f1a V, et al. Clinical profile and ventricular arrhythmias after sacubitril\/valsartan initiation. Cardiology. 2019;142:26\u20137.","journal-title":"Cardiology."},{"key":"7015_CR78","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","volume":"108","author":"P Martens","year":"2019","unstructured":"Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol. 2019;108:1074\u201382.","journal-title":"Clin Res Cardiol"},{"key":"7015_CR79","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.amjcard.2019.09.020","volume":"124","author":"EM Giblin","year":"2019","unstructured":"Giblin EM, Adams KF Jr, Hill L, et al. Comparison of hydralazine\/nitrate and angiotensin receptor neprilysin inhibitor use among black versus nonblack Americans with heart failure and reduced ejection fraction (from CHAMP-HF). Am J Cardiol. 2019;124:1900\u20136.","journal-title":"Am J Cardiol"},{"key":"7015_CR80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000498984","volume":"142","author":"L Vicent","year":"2019","unstructured":"Vicent L, Ayesta A, Esteban-Fern\u00e1ndez A, et al. Sex influence on the efficacy and safety of sacubitril\/valsartan. Cardiology. 2019;142:73\u20138.","journal-title":"Cardiology."},{"key":"7015_CR81","doi-asserted-by":"crossref","first-page":"100","DOI":"10.14740\/jocmr4076","volume":"12","author":"R De Vecchis","year":"2020","unstructured":"De Vecchis R, Paccone A, Di Maio M. Favorable effects of sacubitril\/valsartan on the peak atrial longitudinal strain in patients with chronic heart failure and a history of one or more episodes of atrial fibrillation: a retrospective cohort study. J Clin Med Res. 2020;12:100\u20137.","journal-title":"J Clin Med Res"},{"key":"7015_CR82","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2459\/JCM.0000000000000932","volume":"21","author":"A Valentim Gon\u00e7alves","year":"2020","unstructured":"Valentim Gon\u00e7alves A, Galrinho A, Pereira-da-Silva T, et al. Myocardial work improvement after sacubitril-valsartan therapy: a new echocardiographic parameter for a new treatment. J Cardiovasc Med (Hagerstown). 2020;21:223\u201330.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"7015_CR83","first-page":"1","volume":"15","author":"P D\u00edez-Villanueva","year":"2020","unstructured":"D\u00edez-Villanueva P, Vicent L, de la Cuerda F, et al. Left ventricular ejection fraction recovery in patients with heart failure and reduced ejection fraction treated with sacubitril\/valsartan. Cardiology. 2020;15:1\u20138.","journal-title":"Cardiology."},{"issue":"19","key":"7015_CR84","first-page":"30308","volume":"S1109-9666","author":"ES Nakou","year":"2019","unstructured":"Nakou ES, Marketou ME, Patrianakos A, Protonotarios A, Vardas PE, Parthenakis FI. Short-term effects of angiotensin receptor-neprilysin inhibitors on diastolic strain and tissue Doppler parameters in heart failure patients with reduced ejection fraction: a pilot trial. Hellenic J Cardiol. 2019;S1109-9666(19):30308\u20132.","journal-title":"Hellenic J Cardiol"},{"key":"7015_CR85","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3389\/fphar.2019.01285","volume":"10","author":"Y Suo","year":"2019","unstructured":"Suo Y, Yuan M, Li H, et al. Sacubitril\/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload-induced mice. Front Pharmacol. 2019;10:1285.","journal-title":"Front Pharmacol"},{"key":"7015_CR86","doi-asserted-by":"crossref","first-page":"293","DOI":"10.14740\/cr910","volume":"10","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Paccone A, Di Maio M. Sacubitril\/valsartan therapy for 14 months induces a marked improvement of global longitudinal strain in patients with chronic heart failure: a retrospective cohort study. Cardiol Res. 2019;10:293\u2013302.","journal-title":"Cardiol Res"},{"key":"7015_CR87","first-page":"456","volume":"67","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Paccone A, Di Maio M. Sacubitril\/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction. Minerva Cardioangiol. 2019;67:456\u201363.","journal-title":"Minerva Cardioangiol"},{"key":"7015_CR88","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10554-019-01708-4","volume":"36","author":"I Karagodin","year":"2020","unstructured":"Karagodin I, Kalantari S, Yu DB, et al. Echocardiographic evaluation of the effects of sacubitril-valsartan on vascular properties in heart failure patients. Int J Cardiovasc Imaging. 2020;36:271\u20138.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"19","key":"7015_CR89","first-page":"30264","volume":"S0914-5087","author":"HY Chang","year":"2019","unstructured":"Chang HY, Chen KC, Fong MC, et al. Recovery of left ventricular dysfunction after sacubitril\/valsartan: predictors and management. J Cardiol. 2019;S0914-5087(19):30264\u20133.","journal-title":"J Cardiol"},{"key":"7015_CR90","first-page":"100418","volume":"25","author":"G Bayard","year":"2019","unstructured":"Bayard G, Da Costa A, Pierrard R, Rom\u00e9yer-Bouchard C, Guichard JB, Isaaz K. Impact of sacubitril\/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. Int J Cardiol Heart Vasc. 2019;25:100418.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"7015_CR91","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2459\/JCM.0000000000000851","volume":"20","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Paccone A, Di Maio M. In heart failure with reduced ejection fraction patients' left ventricular global longitudinal strain is enhanced after 1-year therapy with sacubitril\/valsartan compared with conventional therapy with angiotensin-converting enzyme-inhibitors or AT1 blockers: results from a retrospective cohort study. J Cardiovasc Med (Hagerstown). 2019;20:857\u20138.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"13","key":"7015_CR92","doi-asserted-by":"crossref","first-page":"e012272","DOI":"10.1161\/JAHA.119.012272","volume":"8","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc. 2019;8(13):e012272.","journal-title":"J Am Heart Assoc"},{"key":"7015_CR93","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2459\/JCM.0000000000000825","volume":"20","author":"G Santangelo","year":"2019","unstructured":"Santangelo G, Bursi F, Toriello F, et al. Sacubitril\/valsartan improves medium-term reverse left ventricular remodeling: why wait? J Cardiovasc Med (Hagerstown). 2019;20:727\u20139.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"sup1","key":"7015_CR94","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/03007995.2019.1576481","volume":"35","author":"ER Cosentino","year":"2019","unstructured":"Cosentino ER, Degli Esposti D, Miceli R, et al. Sacubitril\/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction. Curr Med Res Opin. 2019;35(sup1):9\u201312.","journal-title":"Curr Med Res Opin"},{"key":"7015_CR95","doi-asserted-by":"crossref","unstructured":"Acanfora D, Scicchitano P, Acanfora C, et al. Early initiation of sacubitril\/valsartan in patients with chronic heart failure after acute decompensation: a case series analysis. Clin Drug Investig. 2020;40(5):493\u2013501.","DOI":"10.1007\/s40261-020-00908-4"},{"key":"7015_CR96","first-page":"1","volume":"2","author":"G Malfatto","year":"2019","unstructured":"Malfatto G, Ravaro S, Caravita S, et al. Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test. Acta Cardiol. 2019;2:1\u20135.","journal-title":"Acta Cardiol"},{"key":"7015_CR97","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2217\/cer-2019-0014","volume":"8","author":"H Morillas-Climent","year":"2019","unstructured":"Morillas-Climent H, Seller-Moya J, Vicedo-L\u00f3pez \u00c1, et al. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril\/valsartan initiation in daily practice. J Comp Eff Res. 2019;8:685\u201397.","journal-title":"J Comp Eff Res"},{"key":"7015_CR98","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jcm8020262","volume":"8","author":"G Vitale","year":"2019","unstructured":"Vitale G, Romano G, Di Franco A, et al. Early effects of sacubitril\/valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction. J Clin Med. 2019;8:262.","journal-title":"J Clin Med"},{"key":"7015_CR99","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/00015385.2018.1521054","volume":"74","author":"CW Lau","year":"2019","unstructured":"Lau CW, Martens P, Lambeets S, Dupont M, Mullens W. Effects of sacubitril\/valsartan on functional status and exercise capacity in real-world patients. Acta Cardiol. 2019;74:405\u201312.","journal-title":"Acta Cardiol"},{"key":"7015_CR100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.recesp.2017.11.019","volume":"72","author":"P Palau","year":"2019","unstructured":"Palau P, Mollar A, Dom\u00ednguez E, Sanchis J, Bay\u00e9s-Gen\u00eds A, N\u00fa\u00f1ez J. Early sacubitril\/valsartan-driven benefit on exercise capacity in heart failure with reduced ejection fraction: a pilot study. Rev Esp Cardiol (Engl Ed). 2019;72:167\u20139.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"7015_CR101","first-page":"1","volume":"18","author":"S Dereli","year":"2020","unstructured":"Dereli S, K\u0131l\u0131n\u00e7el O, \u00c7erik \u0130B, Kaya A. Impact of sacubitril\/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction. Acta Cardiol. 2020;18:1\u20139.","journal-title":"Acta Cardiol"},{"key":"7015_CR102","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nop2.420","volume":"7","author":"L Holmlund","year":"2019","unstructured":"Holmlund L, Br\u00e4nnstr\u00f6m M, Lindmark K, Sandberg C, Hellstr\u00f6m \u00c4K. Health-related quality of life in patients with heart failure eligible for treatment with sacubitril-valsartan. Nurs Open. 2019;7:556\u201362.","journal-title":"Nurs Open"},{"issue":"11","key":"7015_CR103","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jchf.2019.05.016","volume":"7","author":"Y Khariton","year":"2019","unstructured":"Khariton Y, Fonarow GC, Arnold SV, et al. Association between sacubitril\/valsartan initiation and health status outcomes in heart failure with reduced ejection fraction. JACC Heart Fail. 2019;7(11):933\u201341.","journal-title":"JACC Heart Fail"},{"key":"7015_CR104","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jchf.2019.05.015","volume":"7","author":"A Chandra","year":"2019","unstructured":"Chandra A, Vaduganathan M, Lewis EF, et al. PARAGON-HF Investigators. Health-related quality of life in heart failure with preserved ejection fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019;7:862\u201374.","journal-title":"JACC Heart Fail"},{"key":"7015_CR105","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00059-018-4683-5","volume":"44","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Ariano C, Di Biase G, Noutsias M. Cognitive performance of patients with chronic heart failure on sacubitril\/valsartan: a retrospective cohort study. Herz. 2019;44:534\u201340.","journal-title":"Herz."},{"key":"7015_CR106","doi-asserted-by":"publisher","unstructured":"Okutucu S, Fatihoglu SG, Sabanoglu C, et al. Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction. Herz. 2019. https:\/\/doi.org\/10.1007\/s00059-019-04872-4.","DOI":"10.1007\/s00059-019-04872-4"},{"issue":"sup1","key":"7015_CR107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/03007995.2019.1576484","volume":"35","author":"N Marchitto","year":"2019","unstructured":"Marchitto N, Sindona F, Mobilia P, Dalmaso SG, Raimondi G. Effect of low-dose sacubitril\/valsartan on body composition, bioelectrical impedance analysis, heart rate variability and T-peak to T-end index in elderly patients with severe chronic heart failure: a pilot experience. Curr Med Res Opin. 2019;35(sup1):13\u20135.","journal-title":"Curr Med Res Opin"},{"key":"7015_CR108","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jelectrocard.2018.11.015","volume":"52","author":"FJ Pastor-P\u00e9rez","year":"2019","unstructured":"Pastor-P\u00e9rez FJ, Garc\u00eda-Alberola A, Navarro-Pe\u00f1alver M, et al. Lack of improvement in autonomic cardiac tone after sacubitril\/valsartan at lower than target doses. J Electrocardiol. 2019;52:99\u2013100.","journal-title":"J Electrocardiol"},{"key":"7015_CR109","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/00015385.2018.1535818","volume":"75","author":"S Okutucu","year":"2020","unstructured":"Okutucu S, Sabanoglu C, Yetis Sayin B, Aksoy H, Bursa N, Oto A. Switching from ramipril to sacubitril\/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction. Acta Cardiol. 2020;75:20\u20135.","journal-title":"Acta Cardiol"},{"key":"7015_CR110","first-page":"1","volume":"322","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr, Prescott MF, Butler J, et al. PROVE-HF Investigators. Association of change in N-terminal pro-B-type Nvatriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019;322:1\u201311.","journal-title":"JAMA."},{"key":"7015_CR111","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ejhf.1589","volume":"22","author":"M Abellas-Sequeiros","year":"2020","unstructured":"Abellas-Sequeiros M, Del Prado DS, Del Rey JM, Alonso-Salinas GL, Zamorano JL. Sacubitril\/valsartan and B-type natriuretic peptide value: recalculating route. Eur J Heart Fail. 2020;22:162\u20133.","journal-title":"Eur J Heart Fail"},{"key":"7015_CR112","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1093\/eurheartj\/ehz240","volume":"40","author":"DA Morrow","year":"2019","unstructured":"Morrow DA, Velazquez EJ, DeVore AD, et al. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J. 2019;40:3345\u201352.","journal-title":"Eur Heart J"},{"key":"7015_CR113","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2018.12.063","volume":"73","author":"NE Ibrahim","year":"2019","unstructured":"Ibrahim NE, McCarthy CP, Shrestha S, et al. Effect of neprilysin inhibition on various natriuretic Peptide Assays. J Am Coll Cardiol. 2019;73:1273\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"7015_CR114","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","volume":"73","author":"PL Myhre","year":"2019","unstructured":"Myhre PL, Vaduganathan M, Claggett B, et al. B-type natriuretic peptide during treatment with Sscubitril\/valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019;73:1264\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"7015_CR115","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","volume":"73","author":"MR Zile","year":"2019","unstructured":"Zile MR, O\u2019Meara E, Claggett B, et al. Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol. 2019;73:795\u2013806.","journal-title":"J Am Coll Cardiol"},{"key":"7015_CR116","doi-asserted-by":"crossref","unstructured":"Nougu\u00e9 H, Pezel T, Picard F, et al. Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail. 2019;21(5):598\u2013605.","DOI":"10.1002\/ejhf.1342"},{"key":"7015_CR117","unstructured":"Chalikias G, Kikas P, Thomaidis A, et al. Effect of sacubitril\/valsartan on circulating catecholamine levels during a 6-month follow-up in heart failure patients. Timeo Danaos et dona ferentes? Acta Cardiologica."},{"key":"7015_CR118","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ejhf.1451","volume":"21","author":"NL Pereira","year":"2019","unstructured":"Pereira NL, Desai VK, Jaffe AS. Beneficial effects of sacubitril\/valsartan in heart failure with reduced ejection fraction: pas \u00e0 cause du BNP? Eur J Heart Fail. 2019;21:609\u201312.","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07015-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:02:56Z","timestamp":1696222976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07015-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":118,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["7015"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07015-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"9 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}